Friday, January 27, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

RFI for Chem-Bio Threat Diagnostic Device

by Stephanie Lizotte
March 16, 2012

The Defense Threat Reduction Agency (DTRA) Research and Development Enterprise Chemical and Biological Technologies Directorate (RD-CB) continues the effort towards development of a simple to use field diagnostic device with current Request for Information (RFI) numbered DTRA-12-CBA-0002.

The agency seeks details on existing devices or technologies that upon successful completion could be used in the diagnosis of diseases whose cause is an infectious agent or toxin. Such a device should be “low resource and low complexity,” and be FDA approved or compatible with FDA clearance. These devices should follow appropriate FDA regulations as well as the Clinical Laboratory Improvement Amendment (CLIA)-waiver designations.

The RFI is specifically directed at collecting information on the following two use cases:

(1) Highly robust self-collection and presumptive diagnostic screening modality (analogous to home glucose testing), medical diagnostic devices demonstrating CLIA-waived status/low complexity, for use in austere environments and capable of entry to “telemedicine” electronic treatment hierarchy and defined reflexivity to higher level of care.  Such a device should demonstrate sufficient analytical sensitivity and negative predictive value for infectious disease screening applications.

(2) Handheld and CLIA-waived diagnostic devices that are designed for diagnostic or confirmatory field use by a medically trained operator in a “primary care” setting (i.e., field clinic, urgent care facility, Level 1 Medical Treatment Facility,  Shock Trauma Platoon, etc.). Such a device should demonstrate sufficient analytical sensitivity, specificity and total (positive and negative) predictive value for infectious disease diagnostic and confirmatory applications.

In both cases, information is sought for medical diagnostic devices that have been designed to deliver information that will be used to facilitate the diagnosis of diseases whose origin is an infectious agent pathogen or toxin (organized as panels by syndromic presentation or pathogen class), and/or biomarkers of exposure to said agents. Analytes of interest include both pathogen and pathogen class-differential diagnostic markers.

DTRA RD-CB Joint Science and Technology Office (JSTO) is leading the scientific and technology effort for the Department of Defense CB programs through basic and applied research and experimental development related to chemical and biological threat agent characterization, medical diagnostic methods and medical pre-treatment and therapeutic countermeasures, and physical decontamination, detection, protection, and decision support capabilities.

The RFI is open to the in-vitro diagnostic and biotechnology industry, academic, research institute, national or military laboratories sources. The response deadline is March 28, 2012.

Tags: BiomarkersChemical DetectionDefense Threat Reduction AgencyPOC DiagnosticsRFIRuggedized

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
two soldiers are in head-to-toe hazmat suits with respirator masks while tending to a mannikin on a stretcher
CBRNE

Protection from Biothreats: DOD to Modernize Medical Countermeasures Development

January 10, 2023
Killing Anthrax More Quickly with Hot Air Decontamination
CBRNE

Killing Anthrax More Quickly with Hot Air Decontamination

January 4, 2023
New Material Helps Train First Responders on Biothreats
Biodetection

New Material Helps Train First Responders on Biothreats

January 4, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC